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Nuclear orphan receptor Nur77 has important roles in many biological processes. However, a physiological ligand for Nur77 has
not been identified. Here, we report that the octaketide cytosporone B (Csn-B) is a naturally occurring agonist for Nur77. Csn-B
specifically binds to the ligand-binding domain of Nur77 and stimulates Nur77-dependent transactivational activity towards target
genes including Nr4a1 (Nur77) itself, which contains multiple consensus response elements allowing positive autoregulation in a
Csn-B–dependent manner. Csn-B also elevates blood glucose levels in fasting C57 mice, an effect that is accompanied by
induction of multiple genes involved in gluconeogenesis. These biological effects were not observed in Nur77-null (Nr4a1/)
mice, which indicates that Csn-B regulates gluconeogenesis through Nur77. Moreover, Csn-B induced apoptosis and retarded
xenograft tumor growth by inducing Nur77 expression, translocating Nur77 to mitochondria to cause cytochrome c release.
Thus, Csn-B may represent a promising therapeutic drug for cancers and hypoglycemia, and it may also be useful as a reagent
to increase understanding of Nur77 biological function.
Nuclear receptors play important roles in numerous biological pro-
cesses, including cell proliferation, differentiation, apoptosis, meta-
bolism and development1,2. They constitute an important group of
molecules for drug targets as well. The orphan receptors, Nur77 (also
known as TR3, NGFI-B, TIS1 and NAK-1), Nurr1 (RNR-1, TINUR
and HZF-3) and NOR1 (MINOR, CHN and TEC), belong to the
nuclear receptor subfamily 4 group A (NR4A)3,4, which act as
transcription factors to regulate the expression of target genes by
targeting their response elements5,6.
A role for Nur77 in apoptosis was first reported in 1994—Nur77
mRNA was shown to be induced by T-cell receptor signaling,
and Nur77 was shown to be required for T-cell receptor-mediated
apoptosis7,8. Overexpression of a dominant-negative Nur77 or
knockdown of Nur77 expression by antisense RNA inhibited T-cell
receptor-induced apoptosis7,8. The closely related orphan receptor
NOR1 also plays a key role in apoptosis of T lymphocytes, eosinophils
and various other cell types9,10. Additionally, in response to
apoptosis stimuli, Nur77 migrates from the nucleus to the cyto-
plasm where it directly targets the mitochondria to initiate cell
apoptosis11,12. Notably, retinoid X receptor a (RXRa) acts as a
carrier to assist Nur77 translocation from the nucleus to the mito-
chondria in the presence of 9-cis-retinoic acid, an RXR ligand. In the
mitochondria, Nur77 (not RXRa) causes the release of cytochrome
c (ref. 13).
Recently, it has been reported that Nur77, along with two other
subfamily members (Nurr1 and NOR1), has a critical role in glucose
homeostasis. Adenoviral expression of Nur77 induces genes involved
in gluconeogenesis, stimulates glucose production and raises blood
glucose levels14. Nur77 is a positive regulator of G6pc, Fbp1, Fbp2 and
Eno3, which act to increase the glucose pool for hepatic output.
Overexpression of NOR1 also increases insulin-augmented glucose
transport in 3T3-L1 adipocytes15. It is conceivable that increased
sensitivity of insulin may be a consequence of increased blood glucose
levels15. Though much remains to be clarified as to how NOR1
regulates glucose homeostasis, these findings indicate that the Nur77
homolog NOR1 also plays an important role in regulating blood
glucose levels. One may hypothesize that the NR4A subfamily mem-
bers are potential targets for treatment of metabolic diseases.
As with other nuclear receptors, Nur77 has common structural
features with an N-terminal domain that contains an activation
function 1 (AF-1), a DNA binding domain (DBD), a C-terminal
domain that contains the ligand binding domain (LBD), and a ligand-
dependent transcriptional activation domain, AF-2 (ref. 16). However,
a physiological ligand for Nur77 has not been identified. Structural
analysis of the putative ligand binding domain of Nurr1 and the
Drosophila melanogaster ortholog of NOR1 reveals a ligand binding
pocket in these receptors, although one study suggests that the
putative ligand pocket is blocked by side chains from six different
Received 28 May; accepted 14 July; published online 10 August 2008; doi:10.1038/nchembio.106
1Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, 422 South Siming Road, Xiamen,
Fujian 361005, China. 2Center for Integrated BioSystems, Utah State University, 4700 Old Main Hill, Logan, Utah 84322, USA. 3These authors contributed equally to
this work. Correspondence should be addressed to Q.W. (qiaow@xmu.edu.cn), Y.S. (yshen@xmu.edu.cn) or S.-C.L. (linsc@xmu.edu.cn).












































residues17–19. Previous studies found that synthetic compounds
known as DIMs act as agonists to stimulate the pro-apoptotic
functions of Nur77 directly at the transcriptional level20,21. However,
some of the pro-apoptotic effects of DIMs are receptor independent21,
which suggests that there may not be a physical interaction between
the DIMs and Nur77.
We are interested in the regulation of Nur77 and in identifying
naturally occurring compounds that alter Nur77 functions, especially
those related to its ability to modulate transactivational activity and
apoptosis. In the present study, we identified the octaketide Csn-B
(ref. 22), which was isolated from Dothiorella sp. HTF3, an endophytic
fungus, to be a naturally occurring agonist for Nur77. Csn-B has a
strong affinity for Nur77 and stimulates the transactivational activity
of Nur77. Moreover, Csn-B increases Nur77-mediated induction of
apoptosis, increases growth inhibition of xenograft tumors in nude
mice, and enhances gluconeogenesis in mouse liver. Importantly, Csn-
B did not exert any of these effects in Nur77-null mice or cells. These
lines of evidence not only indicate that Csn-B indeed acts as an agonist
for Nur77, but also reveal that Csn-B may be useful in the develop-
ment of new therapeutic drugs to treat cancer and hypoglycemia.
RESULTS
Identification of Csn-B as an agonist for Nur77
To identify potential Nur77 agonists, a bank of natural products
isolated from endophytic fungi was screened using a luciferase-linked
Nur77 reporter gene containing an Nur response element (NurRE)5.
We discovered that the octaketide Csn-B (1)22 (Fig. 1a) stimulates
Nur77-dependent transcriptional activity (Fig. 1b). However, this was
not observed in cytosporone C (Csn-C, 2), a structurally related
derivative (Fig. 1a,b). Csn-B stimulated the transcriptional activation
of the NurRE reporter gene in a dose-dependent manner in gastric
cancer cells BGC-823 (Fig. 1b), whereas it had no influence on the
transcription of reporter genes for the retinoic acid receptor response
element (RARE) (Fig. 1b), estrogen receptor response element (ERE)
or thyroid receptor response element (TRE) (Supplementary Fig. 1
online), thus indicating target specificity.
We next used molecular modeling with the crystal structure of
Nur77 to analyze whether Csn-B can bind to Nur77. By superimpos-
ing the Csn-B structure onto the predicted ligand binding domain
(Fig. 1c) to determine the possible bonding partners, we observed one
hydrogen bond between Csn-B and the hydroxyl group of Tyr453
(Fig. 1c). In addition to the hydrogen bonding of the aromatic head of
Csn-B, the alkyl tail may form hydrophobic interactions with the
hydrophobic residues that were aligned on the surface of the ligand
binding domain of Nur77. Therefore, this molecular modeling
revealed that Tyr453 is situated on the surface of a pocket. More
importantly, the six hydrophobic residues (Fig. 1c) that were believed
to block the putative ligand binding pocket in both Nurr1 and NOR1
(refs. 17,18) were buried interior to the pocket in Nur77.
Csn-B physically binds to Nur77
The molecular modeling of Nur77 proposed above infers a physical
binding of Csn-B to Nur77 (see Fig. 2a for a map of Nur77 domains).
We thus tested this possibility with a number of methods. First, we
determined the physical interaction between this compound and Nur77
by fluorescence quenching analysis. Glutathione S-transferase (GST)-
Nur77 displayed maximal fluorescence at 336 nm (Fig. 2b), whereas
Csn-B itself had no fluorescence at this wavelength (Supplementary
Fig. 2a online). When the GST-Nur77 protein was incubated with
increasing amounts of Csn-B, the fluorescence intensity gradually
decreased (Fig. 2b), whereas Csn-C did not have such an effect
(Supplementary Fig. 2b). We then determined which domain of
Nur77 is involved in Csn-B binding by generating truncation mutants
GST-DBD and GST-LBD, which respectively carry the DNA binding
domain and the ligand binding domain containing the activating do-
main of AF-2 (Fig. 2a). The fluorescence intensity of GST-LBD, but not
GST-DBD, was quenched with increasing amounts of Csn-B (Fig. 2b),
but not Csn-C (Supplementary Fig. 2c), which indicates that Csn-B
physically interacts with the ligand binding domain. Given that mole-
cular modeling and sequence alignment indicate that residue Tyr453 is
conserved in the ligand binding pockets of many nuclear receptors23–26






























































































Figure 1 Identification of Csn-B as a Nur77 agonist.
(a) Structures of Csn-B (1) and Csn-C (2). (b) Csn-B
stimulates Nur77-dependent transcriptional activity in
BGC-823 cells. Reporter gene for Nur77 (NurRE) or
retinoic acid receptor (RARE), together with b-galactosidase
expression vector, was transiently transfected into cells.
16 h after transfection, cells were treated with Csn-B or
Csn-C (9-cis-RA (3) was used as a positive control) for 12 h
at different concentrations as indicated, and the activities of
the reporter gene were determined by luciferase assay and
normalized to the b-galactosidase activity. The basal level of
transcriptional activity was normalized to 1. The bars
represent means ± s.e.m. from three independent
experiments. (c) Molecular modeling of the Nur77 LBD and
its interaction with Csn-B in vitro. The left panel shows a ribbon structure of the Nur77 ligand binding domain; Tyr453 is marked in gray. The right panel
shows a superimposition of Csn-B (yellow) onto the ribbon structure of the Nur77 ligand binding domain. Hydrophobic residues are marked in blue. The
modeling was based on the newly released crystal structure of Nur77 (PDB code 2QW4).
ART ICL ES











































Csn-B binding. Indeed, Nur77 Y453A was no longer quenched in
fluorescence emission by Csn-B at various concentrations (Fig. 2b).
These data not only indicate that Csn-B interacts with the LBD of
Nur77, but also suggest that Tyr453 is instrumental in Csn-B binding.
In addition, we also found that the fluorescence intensity decreased
to a minimum as saturation of the GST-Nur77 protein or GST-LBD
protein with Csn-B was achieved (Supplementary Fig. 2d), which
may reflect specific binding of Csn-B to the ligand binding domain of
Nur77. However, such an effect was not seen in GST-DBD or GST-
Y453A (Supplementary Fig. 2e). To exclude the possibility that this
quenching was caused by an inner filter effect, we used GST as a
control. We observed only a marginal linear decrease of fluorescence
that indicated inner filter (Supplementary Fig. 2d). When the
fluorescence from inner filter was deducted, a corrected fluorescence
intensity curve was obtained (Supplementary Fig. 2d). As a positive
control, 9-cis-retinoic acid (9-cis-RA, 3) binding resulted in fluores-
cence quenching of its receptor, RXRa protein (Supplementary
Fig. 2f), as previously reported27. Moreover, plotting of the data
from which the inner filter effect was deducted yielded titration curves
for Nur77, LBD and RXRa, which we used in a previously described
equation28 to reach apparent dissociation constants (Kd) of 7.4  107
M and 1.51  106 M for Csn-B binding to Nur77 and LBD proteins,
respectively (Supplementary Fig. 2d), and 2.4  107 M for 9-cis-RA
binding to RXRa (Supplementary Fig. 2f). Importantly, the Kd of
9-cis-RA for RXRa that we obtained falls in the range of Kd values
reported previously27.
To further test whether Csn-B is a bona fide agonist for Nur77, we
compared the quenching ability of Csn-B toward Nur77 to that of
several other compounds that are known ligands for different nuclear
receptors, including 9-cis-RA for retinoid receptors13,29, 17-estradiol
(E2, 4) for estrogen receptor30, rosiglitazone (5) for peroxisome
proliferator–activated receptor g (PPARg)31 and prostaglandin E2
(PGE2, 6)32. As E2 and rosiglitazone were found to have an intrinsic
ability to emit fluorescence at a wavelength close to that for
GST-Nur77 (336 nm) (Supplementary Fig. 2a), we discarded them
and decided to use 9-cis-RA and PGE2. Surprisingly, 9-cis-RA and
PGE2 both displayed quenching effects on Nur77, as did Csn-B
(Supplementary Fig. 2g,h). However, whereas Csn-B failed to quench
Y453A (Fig. 1b), the other ligands could still quench the mutant
Y453A (Supplementary Fig. 2g,h). For example, the Kd values for 9-
cis-RA binding to Nur77 and mutant Y453A were similar (7.2  107
M and 8.1  107 M, respectively; Supplementary Fig. 2g,h), which
indicates that Csn-B and 9-cis-RA bind to separate sites.
We then used a biophysical approach to determine the binding
affinity of Csn-B to Nur77. Surface plasmon resonance (BIAcore) was
done to obtain the Kd for Csn-B binding to Nur77. The binding
kinetics for Csn-B were estimated using global fitting analysis of the
titration curves to the 1:1 Langmurian interaction model33. Csn-B
bound GST-Nur77 with an ectodomain pattern (Supplemen-
tary Fig. 2i). The Kd for Csn-B binding to Nur77 was calculated to be
8.52  107 M based on the ratio of the dissociation rate constant
(kd, 7.01  103 s–1) to the association rate constant (ka, 8.23  103
M–1 s–1). In the control, no signal of ectodomain form for binding to
GST appeared (Supplementary Fig. 2i). Csn-B binding to the ligand
binding domain GST-LBD had kinetic constants of kd ¼ 1.73  102
s–1 and ka ¼ 9.05  103 M–1 s–1; the Kd was calculated to be 1.91 
106 M. These values are comparable to those of the full-length of
Nur77. These two Kds were within the same range as those we
obtained from quenching experiments, thus verifying the binding of
Csn-B to Nur77 LBD. In contrast, Csn-B incubation with GST-DBD
or GST-Y453A did not induce an ectodomain pattern (Supplemen-
tary Fig. 2i).
Finally, we performed a CD spectroscopic assay to determine
whether Csn-B induces a conformational change in GST-Nur77.
Csn-B, but not Csn-C, caused a change in the conformation of
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Figure 2 Csn-B physically binds to the ligand binding domain of Nur77. (a) Schematic representations of Nur77 and its truncation mutants. (b) Effect of
Csn-B on fluorescence quenching of GST-Nur77 and its truncation and site mutants. Fluorescence spectra of GST-Nur77, and its truncation and site mutants
(5 mM each), in the absence or presence of increasing amounts of Csn-B. (c,d) Analysis of Csn-B binding to Nur77 and its LBD by CD spectroscopy (c) and
sedimentation equilibrium assay (d) as described in Supplementary Methods.
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contrast, neither compound bound GST-DBD or GST-Y453A to
induce a conformational change (Supplementary Fig. 2j), nor did
addition of 9-cis-RA and PGE2 induce a conformational change in
GST-LBD (Supplementary Fig. 2k), which further confirmed that
these ligands do not have the same binding site as Csn-B. Sedimenta-
tion velocity analysis also indicated the binding of Csn-B with GST-
Nur77 in solution (Fig. 2d). Taken together, these data led us to
conclude that Csn-B specifically interacts with the ligand binding
domain of Nur77, whereas other compounds bind to separate sites of
the protein, as proposed.
Csn-B stimulates transactivational activity of Nur77
To delineate structural determinants of Nur77 in its response to Csn-B
for transactivation, we first determined whether the ligand binding
domain of Nur77 is required for Csn-B to stimulate its transcriptional
activity by transfecting different truncated Nur77 constructs into BGC-
823 cells. These cells were transfected with a chimeric GAL4-Nur77
(full-length Nur77), GAL4-DBD (DNA binding domain of Nur77
only), GAL4-LBD (ligand binding domain including an AF-2 region
that has transactivation activity) or GAL4-Y453A, together with a
reporter construct containing five GAL4 response elements linked to a
luciferase reporter gene (pGAL4)20. The result showed that Csn-B
induced luciferase activity in cells that were cotransfected with GAL4-
Nur77 or GAL4-LBD (Fig. 3a), whereas no response was observed in
cells that were cotransfected with GAL4-DBD or GAL4-Y453A (Sup-
plementary Fig. 3a online). The EC50 (the 50% effective concentration
of Csn-B) values of Csn-B for Nur77 and LBD were 2.78  1010 and
1.15  1010 M, respectively (Supplementary Fig. 3b). In comparison,
Csn-B had only a minimal effect on the transactivational activity of
GAL4-Nurr1(LBD) and GAL4-NOR1(LBD) (Supplementary Fig. 3c).
Furthermore, when 9-cis-RA and PGE2 were tested for their effect on
the transactivational activity of Nur77, only Csn-B exhibited strong
induction of Nur77 transactivational activity (Supplementary Fig. 3d).
Taken together, these data support the notion that Csn-B targets the
ligand binding domain of Nur77, which selectively stimulates the
transactivational activity of Nur77.
To check whether Csn-B has any effect on the stability of the Nur77
protein, we determined the protein levels in the transfected cells.
Results showed that the amount of GAL4-Nur77, GAL4-LBD, GAL4-
DBD and GAL4-Y453A proteins were constant before and after Csn-B
treatment (Fig. 3a and Supplementary Fig. 3a), thereby strongly
suggesting that Csn-B indeed upregulates the transactivational activity
of Nur77. To further explore the effect of Csn-B treatment on Nur77,
we carried out an in vitro knockdown experiment by introducing
expression vectors for small RNA (siRNA) against Nur77 or RXRa in
gastric cancer cells BGC-823 (Fig. 3b). Csn-B–induced activity of the
NurRE reporter gene was attenuated by siRNA against Nur77 by
Bthree-fold below the siRNA control (scrambled siRNA), whereas
siRNA against RXRa had no effect on the same reporter gene in the
presence of Csn-B (Fig. 3b).
In addition, we analyzed the functional effect of Csn-B on the
transactivation of Nur77 in vivo by carrying out in vivo hepato-
cyte transfection. In this experiment, wild-type and Nur77-null
(Nr4a1/) C57BL/6 mice were used. The luciferase reporter that is
responsive to Nur77 was mixed with in vivo transfection reagent and
injected into the tail vein of wild-type and Nr4a1/ mice. In the
hepatocytes of wild-type mice, the transcriptional activity of the
reporter was induced Bfive-fold with Csn-B treatment (Fig. 3c).
However, in the Nr4a1/ mice, Csn-B failed to induce the same
reporter, demonstrating a significant difference (P o 0.01) compared
with the wild-type group (Fig. 3c). Similarly, in the Nr4a1/ mice,
in vivo transfection of GAL4-Y453A did not promote the transcrip-
tional activity of reporter gene in the presence of Csn-B, whereas
wild-type Nur77 significantly (Po 0.01) induced the reporter activity
in the presence of the agonist (Fig. 3d). Again, these results indicate
that Csn-B specifically promotes transactivation of Nur77 in vivo.
Notably, we observed that Nr4a1 mRNA levels were also upregu-
lated by Csn-B treatment (Supplementary Fig. 4a online). Sequence
analysis of the Nr4a1 promoter revealed that it contains several
potential monomeric Nur77 binding sites (NBREs) (Supplementary
Table 1 online), which infers the possibility of Nr4a1 autoregulation of
transcriptional activity. Electromobility shift assays (EMSA) showed
that Nur77 bound to the Nr4a1 promoter with a binding affinity
comparable to the positive control elements NBRE or NurRE (dimeric
Nur77 binding site) (Fig. 4a). The specificity of Nur77 binding to the
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Figure 3 Csn-B activates Nur77 transactivational activity. (a) Csn-B
stimulates the transactivational activity of GAL4-Nur77 and GAL4-LBD in
BGC-823 cells. Insets show the expression levels of GAL4-Nur77 and GAL4-
LBD in the transfected cells. BGC-823 cells were transfected with GAL4-
Nur77 or GAL4-LBD, together with GAL4 reporter gene, and then treated
with Csn-B for 12 h at different concentrations, as indicated. (b) Effect of
siRNA against Nur77 or RXRa on Csn-B–induced transactivational activity.
Cells were transfected with si-Nur77, si-RXRa or si-Ctrl (scrambled siRNA),
together with NurRE-luciferase reporter and b-galactosidase expression
vector. The expression levels of endogenous Nur77 and RXRa are shown
in the insets. (c) Effect of Csn-B on Nur77 transactivational activity in vivo.
Nur77, NurRE-luciferase reporter and b-galactosidase were mixed with an
in vivo transfection reagent and injected into the tail vein of wild-type or
Nr4a1/ mice (n ¼ 5 for each group). After 5 h, mice were administered
with vehicle (DMSO, 50 ml) or Csn-B (50 mg kg–1) intraperitoneally. The
luciferase activities in liver lysates were determined at 24 h post-injection.
Data are presented as means ± s.e.m. **P o 0.01. (d) Nur77-Y453A is not
activated by Csn-B. GAL4-Nur77 or GAL4-Y453A, GAL4-luciferase reporter
genes, and b-galactosidase were transfected into Nr4a1/ mice (n ¼ 5 for
each group), and luciferase activities were determined (P o 0.01) as
described for Figure 3c.
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bind to the promoter when its conserved elements were mutated
(Fig. 4a). To more precisely define the binding motif in the promoter,
we constructed several luciferase reporters containing the Nr4a1
promoter of various lengths, including –500 to +22, –2,900 to +22,
and –3,500 to +22 (pLuc-500, pLuc-2900 and pLuc-3500, respec-
tively). Luciferase reporter assays showed that treatment of Csn-B
stimulated the transcriptional activity of reporter genes pLuc-2900
and pLuc-3500 (which contains consensus Nur77 response elements),
whereas Csn-B did not have any effect on pLuc-500, which did not
carry the Nur77 binding site (Supplementary Fig. 4b). Thus, Csn-B
exerts its effect on Nur77 mRNA levels at least partially through
positive autoregulation.
Previous studies demonstrated that Nur77 requires coactivators
such as SRC-1 and SRC-2 (steroid receptor coactivators) for the
transactivation of target genes34,35. GST pull-down assays indicated
that Nur77 interacts with SRC-1, SRC-2 and weakly with SRC-3 in
293T cells, and that Csn-B treatment enhances Nur77 association with
SRC-2 and SRC-1, but not with SRC-3 (Fig. 4b). We then investigated
whether an Csn-B–activated Nur77-SRC association promotes the
recruitment of the coactivators to Nur77 response elements. To this
end, we performed chromatin immunoprecipitation (ChIP) assays
using NurRE as a probe and analyzed the recruitment of SRC
cofactors. Csn-B recruited SRC-2 and to a lesser extent SRC-1, but
not SRC-3, to NurRE (Supplementary Fig. 4c). SRC-2 and SRC-1
consistently enhanced the transactivational activity of Nur77, which
was further stimulated by Csn-B in a dose-dependent manner
(Fig. 4c). Together, these data indicate that the transactivational
activity of Nur77 is activated by Csn-B, which also promotes recruit-
ment of the coactivators SRC-2 and SRC-1.
Csn-B increases blood glucose levels
Nur77 increases blood glucose concentrations by enhancing gluconeo-
genic gene expression14. If Csn-B is a genuine agonist for Nur77, it is
expected that Csn-B would also elicit such an effect on blood glucose
levels (Fig. 5). To analyze the biological function of Csn-B in Nur77-
mediated regulation of glucose levels, we tested the levels of blood
glucose in wild-type and Nr4a1/ mice. Csn-B significantly (P o
0.01) changed blood glucose levels in fasting wild-type mice (Fig. 5a).
In wild-type mice, after fasting for 16 h, the basal levels of blood glucose
declined to 3.2 mM. However, Csn-B treatment significantly increased
glucose levels from 3.2 to 11.4 mM (P o 0.01) within the first 30 min,
and thereafter blood glucose gradually decreased before reaching the
initial level after 300 min (Fig. 5a). By contrast, in Nr4a1/ mice Csn-
B induced a diminished increase in glucose levels within the first 30
min (from 3.7 to 5.8 mM) as compared with the wild type, which was
close to the effect of control injections (Supplementary Fig. 5a online).
Multiple genes that participate in the gluconeogenic and glycolytic
pathways are induced by Nur77 overexpression in mouse hepatocytes
and skeletal muscle14,36. Given that Nur77 affects gluconeogenesis and
glycolysis, we hypothesized that Csn-B may regulate related genes in
these two pathways mediated by Nur77. To test this hypothesis, we
chose several genes for real-time PCR analysis, including the genes
encoding glucose-6-phosphatase (G6pc) and fructose-1,6-bisphopha-
tase (Fbp1) for the gluconeogenesis pathway, and the genes encoding
hexokinase (Hk), phosphofructokinase (Pfk) and pyruvate kinase (Pk)
for the glycolysis pathway14. Cellular mRNA was prepared from the
livers of wild-type and Nr4a1/ mice that were treated with Csn-B.
We observed after 30 min of Csn-B treatment that expression
significantly (P o 0.01) increased for G6pc (4.1-fold) and Fbp1
(3.0-fold), as compared with the control (Fig. 5c). Concomitant
with the glucose level changes, 300 min after administration of Csn-
B, the expression levels of these genes returned to initial levels
(Fig. 5c). However, we did not observe any change in gene expression
of Hk, Pfk or Pk after 30 to 300 min of Csn-B treatment in wild-type
mice (Fig. 5c). Importantly, the Csn-B effect on the glucogenogenic
genes was not observed in Nr4a1/ mice (Supplementary Fig. 5b).
These results indicate that Csn-B only influences gluconeogenesis, and
that Csn-B depends on Nur77 to exert changes in this pathway.
As insulin acts to reduce blood glucose levels and Csn-B elevates
blood glucose levels, we next investigated whether Csn-B has an
antagonistic effect on insulin. As expected, a Bthree-fold reduction
of glucose levels in insulin-treated mice occurred within 30 min
(Fig. 5b). However, in the mice treated with insulin and Csn-B
together, Csn-B was able to abrogate the decline of glucose levels
caused by insulin administration. Quantitative real-time PCR showed
an increase in G6pc and Fbp1 expression in liver of 6.23- and 3.05-fold,
respectively, in insulin plus Csn-B treatment after 60 min (Supple-
mentary Fig. 5c). Therefore, the expression patterns of the gluconeo-
genic genes correlate with the glucose concentration changes in mice
cotreated with Csn-B and insulin.
Csn-B induces apoptosis by targeting Nur77 to mitochondria
Next we tested for the ability of Csn-B to induce apoptosis in vitro in
cancer cells given that Nur77 is implicated in induction of apopto-
sis11,12,37. Indeed, Csn-B displayed robust pro-apoptotic activity in
gastric cancer cells BGC-823. We observed 63.5% of the cells to be
apoptotic when treated with Csn-B for 48 h (Fig. 6a). Induction of
apoptosis by Csn-B was closely related to Nur77 activity, as introduc-
tion of siRNA against Nur77 into BGC-823 cells resulted in a
B2.5-fold reduction in Csn-B–induced apoptosis (20.1%) as com-
pared with the siRNA control (56.3%) (Fig. 6a). The Csn-B–induced
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Figure 4 Csn-B mediates Nur77 autoregulation and cofactor recruitment.
(a) EMSA of the Nr4a1 promoter. GST-Nur77 proteins were incubated with
biotin-labeled oligonucleotides that are NBRE elements present in the
Nr4a1 promoter, and with their mutant forms, along with a consensus
NBRE and NurRE as positive controls (nucleotide sequences shown in
Supplementary Methods). (b) Csn-B enhances interaction of Nur77 with
SRCs, as detected by GST pull-down assay. GST-Nur77 or GST alone was
incubated with cell lysates from 293T cells that were transfected with Flag-
SRC-1, Flag-SRC-2 or Flag-SRC-3 and Csn-B (106 M) for 3 h. Inputs
indicate relative expression levels of SRC proteins. (c) Effect of SRCs on
Csn-B–induced Nur77 transactivation. BGC-823 cells were transfected
with or without SRC-1, SRC-2 or SRC-3, NurRE-luciferase reporter and
b-galactosidase, and were treated for 12 h with different concentrations of
Csn-B. The fold induction was derived by comparing each luciferase activity
to non-SRC transfection for a given concentration of Csn-B. All results are
presented as means ± s.e.m.
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apoptotic cells displayed characteristic nuclear DNA condensation
(Supplementary Fig. 6a online), resulting in cytochrome c release
and caspase-9 cleavage (Supplementary Fig. 6b). However, Csn-C did
not induce apoptosis (Supplementary Fig. 6c) or release of cyto-
chrome c (Supplementary Fig. 6d) in BGC-823 cells.
Several lines of recent evidence suggest that Nur77-mediated
apoptosis is associated with Nur77 nucleocytoplasmic translocation
accompanied by transcriptional regulation11–13,37. Therefore, we
examined the subcellular localization of Nur77 in response to Csn-B
stimulation using confocal microscopy. To establish a baseline, a GFP-
Nur77 fusion construct was transfected into BGC-823 cells to test the
subcellular location of Nur77. GFP-Nur77 was found in the mito-
chondria of about 70% of cells with treatment of Csn-B. In contrast,
without Csn-B addition, Nur77 was exclusively localized in the
nucleus of more than 90% of cells (Fig. 6b). Addition of Csn-B, but
not of Csn-C, induced nuclear export of endogenous Nur77 in BGC-
823 cells; however, such nucleocytoplasmic translocation was blocked
by leptomycin B (LMB, 7), a specific inhibitor of nuclear protein
export (Fig. 6c). After LMB treatment, Csn-B was able to promote
translocation of Nur77 to the cytoplasm in only approximately 15% of
transfected cells (Supplementary Fig. 6e). Mutation at Tyr453 in
Nur77 resulted in the loss of translocation in the presence of Csn-B;
almost no cytoplasmic localization of Nur77 was observed (Supple-
mentary Fig. 6f). Together, these results suggest that Csn-B induces
Nur77-mediated apoptosis through relocalization of Nur77 from the
nucleus to the mitochondria.
Csn-B inhibits cancer cell proliferation and tumor growth
The apoptotic action of Csn-B via its binding to Nur77 prompted us
to further investigate the anticancer activity of Csn-B with in vitro
proliferation assays and in vivo by examining growth repression of
xenograft tumors in nude mice. MTT (3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyltetrazolium bromide) assays indicated that Csn-B inhib-
ited proliferation of human gastric cancer BGC-823 cells and human
colon cancer SW620 cells by 470% (Fig. 7a), but it had a modest
effect on human lung cancer H1299 cells and human hepatoma HepG2
cells (inhibition Z 40%) and a small effect on mouse NIH3T3
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Figure 5 Csn-B increases blood glucose levels
and expression of gluconeogenic genes.
(a,b) Effect of Csn-B on blood glucose levels in
wild-type mice. Wild-type mice were fasted for
16 h before Csn-B (50 mg kg–1) or glucose
(2 g kg–1) injection (a), or for 5 h before insulin
(0.5 U kg–1) injection (b). Glucose levels were
recorded at different times as indicated. DMSO
(50 ml) was used as a vehicle control. Control
group refers to the mice that received only an
injection without any vehicle. (c) Effect of Csn-B
on mRNA expression levels of gluconeogenic and
glycolytic genes. Livers of mice were dissected at
different times indicated after administration of
Csn-B. Total RNA was prepared, and the mRNA
levels of different genes were analyzed by real-
time PCR. The fold induction was plotted against
the DMSO treatment for all given time points. All
results are presented as means ± s.e.m.
Representatives of two independent experiments
with similar results are shown. **P o 0.01.
Figure 6 Csn-B induces apoptosis via Nur77 in
BCG-823 cells. (a) Induction of apoptosis by
Csn-B. Cells were transfected with or without
si-Nur77 and si-Ctrl (scrambled siRNA) as
indicated, and then treated with Csn-B (5 mg
ml–1) for 48 h. Apoptotic cells were determined
by flow cytometry assay. (b) Nur77 was
translocated to the mitochondria upon Csn-B
treatment. GFP-Nur77–transfected cells were
treated with Csn-B (5 mg ml–1) for 12 h, then
immunostained with anti-Hsp60 followed by
Texas Red–conjugated antibody. Nur77 protein
was visualized under a confocal microscope.
Scale bar, 10 mm. (c) Translocation of Nur77
from the nucleus to the cytoplasm in response
to Csn-B or Csn-C. Cells were pretreated with or
without LMB (1 ng ml–1) for 3 h, followed by
Csn-B or Csn-C (5 mg ml–1 each) for an additional
12 h. Endogenous Nur77 was stained with
anti-Nur77 antibody, followed by fluorescein
isothiocyanate (FITC)-conjugated antibody. Finally,
the nuclei were stained with 4¢,6-diamidino-2-
phenylindole (DAPI). Scale bar, 10 mm.
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hepatoblasts from mouse E13.5 liver (Supplementary Fig. 6g). These
results indicate a selective effect of Csn-B on cancerous cells.
In vivo determination of the antitumor effect of Csn-B was carried
out by injecting gastric cancer cells BGC-823 subcutaneously into nude
mice (n ¼ 6). One week later, Csn-B was administered intraperitone-
ally to the recipient nude mice at a dosage of 13 mg kg–1 twice a week.
Four weeks after starting Csn-B administration, tumors were removed
to determine the weight. In parallel, we established two BGC-823 cell
sublines that separately express siRNA against Nur77 (si-Nur77) and a
control siRNA (si-Ctrl) containing alterations in two nucleotides
compared with si-Nur77. These two sublines were also injected into
nude mice, and the xenografts were analyzed. As summarized in
Table 1 and Figure 7b, in normal BGC-823–injected mice (labeled
as Nur77-WT), tumor growth was significantly reduced with Csn-B
treatment (41.6% inhibition in weight, Po 0.05). However, Csn-B did
not inhibit tumor growth in mice injected with si-Nur77 cells (10.2%
inhibition, P 4 0.05) as compared with mice injected with si-Ctrl cells
(43.6% inhibition, P o 0.05). Importantly, the nude mice did not
display any discomfort or discernible side effects in diet intake or
overall body weight during administration of Csn-B.
To further verify the effects of Csn-B on Nur77 function in the
xenograft tumors, we carried out western blots and immunohisto-
chemistry to examine Nur77 expression and localization, as well as
TUNEL (terminal dUTP nick end labeling) assays to detect apoptotic
cells on tissue sections of the xenograft tumors. We found that mice
injected with Nur77-WT (BGC-823) cells or si-Ctrl–expressing cells
contained increased Nur77 protein levels after Csn-B administration
(Fig. 7c and Supplementary Fig. 6h). Csn-B administration also
increased the total number of apoptotic cells in xenograft tumors
derived from BGC-823 cells and from si-Ctrl–expressing cells, but not
from si-Nur77–expressing cells (Fig. 7d). In the specimens injected
with BGC-823 cells, we also noted that Nur77 was present in both the
nuclei and cytoplasm in the Csn-B–treated group, but was present
predominantly in the nuclei of the non-Csn-B–treated group
(Fig. 7c), which is in accordance with the results obtained from cell
treatment experiments. In contrast, Nur77 protein displayed predo-
minant nuclear localization in mice injected with si-Nur77 cells in
both Csn-B–treated and non-Csn-B–treated samples, whereas both
nuclear and cytoplasmic localization in mice injected with si-Ctrl cells
was observed in Csn-B–treated samples but not in non-Csn-B–treated
samples (Fig. 7c). Together, these data agree with our in vitro
observations; they indicate that Csn-B induces Nr4a1 expression by
autoregulation in vivo and that Csn-B causes translocation of Nur77
from the nucleus to the cytoplasm to induce apoptosis in tumor
tissue, thereby inhibiting tumor growth.
DISCUSSION
Despite the fact that the orphan receptor Nur77 is linked to various
important biological functions11,14,29,38,39, no physiological ligand is
known. In this study, we identified Csn-B, an octaketide, as an agonist
for Nur77. We found that Csn-B physically binds to Nur77 and
subsequently activates its transactivational activity and translocation
Figure 7 Csn-B inhibits growth of cancer cells
and xenograft tumors. (a) Csn-B inhibits growth
of cancer cells. Human gastric cancer BGC-823
cells and human colon cancer SW620 cells
were treated with Csn-B for 72 h at various
concentrations, as indicated. The number of
viable cells was determined by MTT assay.
(b) Csn-B effects on the growth of xenograft
tumors in nude mice that were injected with three
different BGC-823 cells, including BGC-823 cells
expressing endogenous wild-type Nur77 (Nur77-
WT), BGC-823 cells with Nr4a1/ knocked down
by its siRNA (si-Nur77), and BGC-823 cells with
Nur77 mutated in its siRNA sequence (si-Ctrl).
Nude mice were administered with Csn-B as
described in the Methods. The xenograft tumors
of various sizes are shown. Scale bar, 1 cm.
(c) Subcellular localization of Nur77 in
the specimens of xenograft tumors.
Immunohistochemistry experiments were carried
out to reveal the localization of Nur77 protein in the three kinds of tumor samples in the non-Csn-B treatment and Csn-B treatment groups. Scale bar, 30 mm.
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Table 1 Effect of Csn-B on repression of tumors in nude mice
Mean weight of mice
Nude mice Rate of tumor occurrence (%) Before treatment After treatment Mean weight of tumor Inhibition (%)
Nur77-WT; Ctrl 100 (6/6) 15.21 ± 1.81 21.96 ± 1.62 1.86 ± 0.34 41.6 (P ¼ 0.003)
Nur77-WT; Csn-B 100 (6/6) 15.81 ± 1.62 20.31 ± 1.73 1.09 ± 0.26
si-Nur77; Ctrl 100 (6/6) 15.35 ± 1.21 20.98 ± 1.50 1.77 ± 0.27 10.2 (P ¼ 0.251)
si-Nur77; Csn-B 100 (6/6) 15.63 ± 1.42 20.52 ± 1.33 1.59 ± 0.20
si-Ctrl; Ctrl 100 (6/6) 16.50 ± 2.01 22.34 ± 1.92 1.95 ± 0.26 43.6 (P ¼ 0.002)
si-Ctrl; Csn-B 100 (6/6) 16.22 ± 2.13 20.87 ± 1.89 1.10 ± 0.20
All data are presented as means ± s.d.
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to mitochondria to induce apoptosis. Further evidence that Csn-B is
an agonist of Nur77 was derived from fluorescence quenching assays,
circular dichroism measurement and BIAcore analysis. We have also
suggested biological functions of Csn-B in glucose metabolism.
Importantly, these functions of Csn-B all agree with the functions
previously identified for Nur77 (refs. 11,14,36,38,40). Moreover, we
have shown that Csn-B depends on Nur77 to selectively activate the
NurRE reporter gene.
Analysis of the crystal structures of mouse Nurr1 LBD and the
Drosophila NOR1 homolog DHR38 (refs. 17–19), and the structure of
Nur77, reveals a potential ligand binding pocket in their LBD. Inside
this pocket, there is a tyrosine residue that is conserved among many
nuclear receptors23–26 and is located at position 453 in Nur77.
Fluorescence quenching experiments showed that Csn-B quenches
the fluorescence of wild-type Nur77, but not the Y453A mutant,
which indicates that the conserved tyrosine residue may form a
contact with Csn-B or that Csn-B binding to the pocket may somehow
cause a conformational change that in turn influences the fluorescence
emission of Tyr453. The importance of Tyr453 was further under-
scored by our in vivo reporter assay, which showed that the wild-type
Nur77 but not the mutant Y453A could be induced by Csn-B to
activate the reporter gene.
Another aspect of functional resemblance of Csn-B to Nur77 is that
Csn-B administration leads to an acute boost of blood glucose levels in
fasting C57 mice. A recent study showed that overexpression of Nur77
by an adenoviral expression system in mice results in enhanced
activity of gluconeogenesis, which is manifested by increased blood
glucose levels and increased expression of gluconeogenic enzymes
encoded by G6pc and Fbp1 (ref. 14). We demonstrated that Csn-B
treatment in wild-type fasting mice could increase blood glucose
levels, and gluconeogenic genes such as G6pc and Fbp1 were all
induced by Csn-B in the liver tissue of mice. Moreover, we demon-
strated that in Nr4a1/ mice, Csn-B did not induce the expression
of the gluconeogenic genes or cause an increase of blood glucose
levels, thereby providing an important line of genetic evidence
indicating that Csn-B elicits biological functions through its
receptor Nur77.
In summary, our work demonstrates that Csn-B is a bona fide
agonist for Nur77. The availability of this natural product will open
new avenues for studying the orphan receptor Nur77. Importantly,
Csn-B may represent a new candidate or lead compound for cancer
treatment and for treating individuals with hypoglycemia.
METHODS
Isolation and characterization of cytosporone B and cytosporone C. Csn-B
and Csn-C were purified from the mycelia of the endophytic fungal strain
Dothiorella sp. HTF3, which was isolated from mangrove trees and cultured in
liquid potato dextrose broth medium. The structures of these compounds were
determined by NMR (Supplementary Table 2 online), and antimicrobial
activities were determined against several species (Supplementary Table 3
online). For more detailed information on fungal fermentation, chemical
extraction and structural determination of the compounds, see Supplementary
Methods online.
Molecular modeling. The three-dimensional geometry data file for Nur77 was
obtained from the Protein Data Bank. Three-dimensional geometry for Csn-B
was created and optimized using the computational chemistry package
Ghemical41 with 0.001 gradient cutoff and 1  107 d E cutoff. AutoDock3.0
(ref. 42) and AutoDockTools (http://autodock.scripps.edu/resources/) were
used to investigate Csn-B binding to Nur77. The search was based on a
Lamarckian genetic algorithm. Default values were selected for Docking
Searching Parameter and Docking Run Parameters. DS Modeling 1.1 (Accelrys)
was used to generate images of Csn-B and Nur77.
Tumor xenograft experiment. Athymic nude mice (BALB/c, SPF grade,
B16 g, four weeks old) were housed in a laminar flow under sterilized
conditions. The temperature was maintained at 28 1C. Mice were fed with
autoclaved mouse chow. The inoculation dosage with BGC-823 cells was
0.05 ml of cell suspension per mouse (cell density was 2.5  1010 l–1). Different
cells, including wild-type BGC-823 cells and BGC-823 cells separately expres-
sing si-Nur77 and si-Nur77-ctrl, were injected subcutaneously into nude mice.
The inoculated mice were randomly separated into two groups. One group was
given an injection to the abdominal cavity at a dosage of 13 mg kg–1 of Csn-B
(one tenth of the dosage lethal to 50% of mice tested (LD50)) twice a week. The
other group was administered with the same dissolvent (DMSO) without Csn-
B. Food consumption and body weight of nude mice were monitored weekly.
Four weeks later, the nude mice were killed and the tumors formed were
removed, fixed and embedded. All results were presented as means ± s.d.
P value was determined by a two-tailed Student’s t-test.
Blood glucose test. Wild-type and Nr4a1/ C57BL/6 mice (six weeks old)
were fasted, with water supply, for 16 h (for glucose tolerance test) or 5 h (for
insulin tolerance test) before blood sampling through the tail vein. Mice were
then injected intraperitoneally with Csn-B at a dosage of 50 mg kg–1. Injections
with glucose (2 g kg–1), insulin (0.5 U kg–1) or DMSO (50 ml), even without
any vehicle, were used as controls. Blood glucose levels were measured at 15, 30,
60, 90, 120, 180 and 300 min after treatment, using a OneTouch Ultra
glucometer (Lifescan). The weights of mice were recorded before every test.
All data are presented as means ± s.e.m. The experiments were carried out in
the Cancer Research Center of Xiamen University under the guidelines of the
Xiamen University Institutional Animal Care and Use Committee.
Other methods. Details for other methods, including cell culture, plasmid
construction, luciferase assay, fluorescence quench assay, BIAcore analysis,
sedimentation equilibrium study, CD spectroscopy, transient transfection,
western blot, apoptosis assay, RT-PCR, real-time PCR, EMSA, ChIP assay,
MTT assay and isolation and structure elucidation of Csn-B and Csn-C, are
provided in the Supplementary Methods.
Accession codes. Protein Data Bank: The crystal structure of Nur77 was
deposited as part of a previous study under accession code 2QW4.
Note: Supplementary information and chemical compound information is available on
the Nature Chemical Biology website.
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